Introduction: Patients with haemophilia on long-acting prophylactic treatment may experience an improvement in health-related quality of life (HRQoL) through reductions in breakthrough bleeds and associated complications, including long-term joint damage, compared with episodic treatment. Aim: This analysis examined clinical trial data to understand the psychometric characteristics (reliability, validity and sensitivity to change over time) of the Haem-A-QoL Questionnaire in adult males with haemophilia. Methods: Two recent, multinational, Phase 3 clinical trials of new, long-acting factor concentrates (A-LONG: rFVIIIFc; B-LONG: rFIXFc) assessed HRQoL in adolescent and adult males with severe haemophilia A or B respectively. The adults' baseline assessments, via the 46-item Haem-A-QoL Questionnaire, and change over time at the 6-month assessment were used in the psychometric analyses. Results: Internal consistency reliability was adequate (Cronbach's alpha > 0.70) for nine of the 10 Haem-A-QoL domains and for 'Total Score' in both trials at baseline (A-LONG, n = 133; B-LONG, n = 73). At baseline, several Haem-A-QoL domains and 'Total Score' demonstrated known-groups and convergent validity when compared with other trial measures, including the EQ-5D (items and total scores) and joint impairment. Change score correlations (baseline to 28 weeks) between the EQ-5D and the Haem-A-QoL 'Total Score', and 'Physical Health' and 'Feelings' domains were moderate in magnitude (│r│ ≥ 0.33; P < 0.03), demonstrating sensitivity to change for these outcome measures in A-LONG. Conclusion: These psychometric analyses provide evidence of the reliability, validity and ability to detect change of the Haem-A-QoL to assess the HRQoL of adult males with severe haemophilia A and B in longitudinal clinical trials.
Introduction
Current haemophilia therapies focus on administering infusions of factor concentrate; when administered prophylactically, these therapies limit damage in chronic joint disease, and improve patients' overall quality of life and functional independence [1] . In two recent, multinational, Phase 3 clinical trials of new, long-acting factor concentrates (A-LONG: rFVIIIFc; B-LONG: rFIXFc), health-related quality of life (HRQoL) was assessed as a secondary endpoint in adults with severe haemophilia A and B, respectively, who received prophylactic or episodic treatment regimens [2, 3] . In designing these trials, it was hypothesized that, in the short term, subjects with haemophilia receiving prophylactic treatment with these products would experience an improvement in HRQoL through a reduction in breakthrough bleeds and a lower infusion frequency (reduced treatment burden). Over a longer term, prophylactic treatment may slow joint damage compared with episodic treatment [4] [5] [6] [7] .
The HRQoL of participants in the A-LONG and B-LONG clinical trials was assessed using the adult version of the Haemophilia-specific Quality of Life (Haem-A-QoL) Questionnaire. This instrument, with results from its use first published in 2005 [8] , has demonstrated internal consistency and reproducibility, as well as crosssectional validity using data from an observational study conducted among an Italian adult population (n = 233) with haemophilia A or B [8, 9] . However, it is necessary to confirm the performance of this instrument in the specific populations and conditions for which it is intended [10] , and there is no published validation of the Haem-A-QoL for use in a multinational population or a longitudinal clinical trial setting.
The A-LONG and B-LONG studies [2, 3] provided the data necessary to study validation of the Haem-AQoL in this specific setting; therefore, the primary objective of this analysis was to investigate the reliability, validity and sensitivity to change of the Haem-A-QoL in adult male, multinational, clinical trial populations with haemophilia A or B. Additionally, within this psychometric investigation, we examined whether the HRQoL of the overall A-LONG and B-LONG populations improved over time, and tested the superiority of prophylaxis over episodic treatment with these novel agents.
Methods

Study design and subject populations
The study designs, full inclusion/exclusion criteria and primary results of A-LONG and B-LONG have been described previously [2, 3] . Study details are included in the Data S1. This psychometric analysis focused only on participants in selected treatment arms of A-LONG and B-LONG who were ≥17 years of age (hereafter referred to as adults), as the Haem-A-QoL is intended for use only in this age group (Fig. 1) . To ensure adequate exposure in each treatment arm, data pooled across treatment groups from the baseline/ screening visit and the Week 28 visit in the A-LONG study, and data from the baseline/screening visit and Week 26 visit in the B-LONG study were included in the investigation of the psychometric properties of the Haem-A-QoL. Only data collected in the efficacy period were used in these analyses, and the efficacy period for each regimen reflects the sum of all intervals of time during which subjects were treated with rFVIIIFc or rFIXFc according to the treatment regimen of the study, excluding major and minor surgical/ rehabilitation periods. In Arms 1 and 2 of A-LONG, the efficacy period started with the first prophylactic dose, following a completed pharmacokinetic (PK) sampling period and ended with the last dose administered; in Arm 3, the efficacy period started 1 min after the last sampling time point for the PK dose and ended with either the last contact or last patient diary entry. For additional explanation of the efficacy period in these studies, please refer to the published clinical trial reports [2, 3] .
Measures
Outcome measures included patient-reported outcomes for the assessment of HRQoL (Haem-A-QoL) [8, 9] and health utility measures [EuroQoL-5 Dimension (EQ-5D)] [11] [12] [13] , as well as the Modified Hemophilia Joint Health Score (mHJHS; modified for use in adults) [14] , change in physical activity questionnaire and bleeding assessments (see Data S1 for additional details). In this analysis, once unidirectional item score values were obtained with the Haem-AQoL, a raw score for each domain of the Haem-AQoL was calculated by summing up all of the item values, provided that the minimum number of questions had been answered for that domain: 'Physical Health' (5), 'Feelings' (4), 'View of Self' (5), 'Sports and Leisure' (5), 'Work and School' (4), 'Dealing With Haemophilia' (3), 'Treatment' (8), 'Future' (5), 'Family Planning' (4) or 'Partnership and Sexuality' (3). The raw scores were transformed to a 0-100 scale, with higher scores representing higher impairments in HRQoL. The 'Total Score' was calculated in the same manner using the transformed raw score summed across all items, provided that at least 38 of the 46 items on the Haem-A-QoL were completed at the study visit. Regarding the EQ-5D index, no imputation due to missing data was applied for the analyses; if a subject had any missing data on the five dimension items at a particular visit, that individual's EQ-5D score was noted as missing at that visit. Regarding the mHJHS, no imputation due to missing data was applied for these analyses.
The change in physical activity questionnaire assessed the level of physical activity of participants since their last study visit; 'Total Scores' were based on the response to one question regarding physical activity. In the B-LONG study, change in physical activity was evaluated during several time points, from baseline to the end of the study. Bleeding was assessed by the annualized bleeding rate (ABR) during the efficacy period. Subject estimates of the number of bleeds in the previous 12 months were also collected at baseline.
Statistical analyses
Analysis population. The data for this psychometric analysis includes all subjects aged ≥17 years who received ≥1 dose of rFVIIIFc (A-LONG) or rFIXFc (B-LONG) and completed a sufficient number of items on the Haem-A-QoL to be scored in ≥1 domain (A-LONG, n = 133; B-LONG, n = 73). Mean, median, range, interquartile range (IQR) and standard deviation (SD) were determined for all domain scores and for the total score of the Haem-A-QoL in the A-LONG and B-LONG study data at baseline. The criterion for statistical significance was P < 0.05, and no adjustments for multiple comparisons were incorporated in these exploratory analyses.
Internal consistency reliability. Internal consistency reliability addresses the extent to which individual items in an instrument are related to one another; Cronbach's alpha (a) > 0.70 supports that items from the same domain measure the same construct [15] . Using the baseline A-LONG and B-LONG data, the internal consistency of the Haem-A-QoL domain scores and total score was investigated using Cronbach's alpha.
Construct validity. Known-groups validity assesses the extent to which scores from an instrument are different for groups of participants that differ on a relevant indicator [16, 17] . Using the A-LONG and B-LONG study data, known-groups validity comparisons using a one-way analysis of variance (ANOVA) for the Haem-A-QoL mean domain and total scores were conducted at baseline separately by: (i) EQ-5D item response categories that were dichotomized by the EQ-5D levels into 'no problems' (Level 1) and 'problems' (Levels 2 and 3; A-LONG only), and (ii) median values as well as 'any' vs. 'none' for number of bleeds in the 12 months prior to study entry were used to dichotomize into two groups as appropriate (median for A-LONG, 1 bleed; median for B-LONG, 3 bleeds).
Convergent validity tests whether different measures of the same construct correlate. The A-LONG study data were used to perform a Pearson correlation analysis of the relationship between the Haem-A-QoL domain and total scores and scores from the mHJHS (hypothesized positive correlations) and the EQ-5D (hypothesized negative correlations) at baseline. Convergent validity was supported when the Haem-AQoL domain and total scores correlations were of magnitude │r│ ≥ 0.30 (indicating at least moderate correlation), with items or scales measuring similar concepts [15, 18] .
Responsiveness. Responsiveness refers to the extent to which the instrument can detect true change in participants who are known to have changed clinical status [17] . Changes in Haem-A-QoL domain and total scores were correlated with changes in ABR, annualized spontaneous bleeding rate, annualized traumatic bleeding rate, the EQ-5D (A-LONG) and the subjects' change in activity questionnaire (B-LONG). Change score correlations for the Haem-A-QoL domain and total scores of a magnitude of │r│ ≥ 0.30 signified that the Haem-A-QoL scale was a sensitive measure of change in HRQoL over time for subjects with haemophilia [18] . The ability to detect change was examined from baseline to Week 28 in the A-LONG study data and from baseline to Week 26 in the B-LONG study data. Tables 1 to 2 show the baseline demographic and clinical characteristics of the subjects included in these analyses of the A-LONG (n = 133) and B-LONG (n = 73) studies, respectively, stratified by treatment arm. In both A-LONG and B-LONG, subjects had the greatest HRQoL impairments at baseline in the 'Sports and Leisure' and 'Physical Health' domains (Table 3) .
Results
A-LONG and B-LONG participant population
A-LONG study design
B-LONG study design 
Reliability
Internal consistency reliability as assessed by Cronbach's alpha was adequate (a > 0.70) for nine of the 10 Haem-A-QoL domains and for the total score in both trials (Table 3) . The reported Cronbach's alphas for the Haem-A-QoL domain scores in the A-LONG study had the highest consistency in the 'Family Planning' and 'Partnership and Sexuality' domains. In the B-LONG study, the Cronbach's alpha for the Haem-A-QoL domain scores had the highest internal consistency in the 'Partnership and Sexuality' domain. For the Haem-A-QoL total score, reliability was high in both studies.
Construct validity
Known-groups validity. Known-groups validity tests compared mean Haem-A-QoL domain and 'Total Scores' for each EQ-5D item between Level 1 responders (no problem) and Level 2 or 3 responders (some problems or extreme problems). In A-LONG, these tests demonstrated the validity of all Haem-A-QoL domain scores (P < 0.05), with the exception of the 'Dealing With Haemophilia' and 'Family Planning' domains, for all EQ-5D items (Table 4 ). In addition, known-groups validity was also demonstrated in the Haem-A-QoL 'Total Score' and several domains based on a dichotomization at the median of 1 bleed in the 12 months prior to study entry (none vs. ≥1 bleeds, P < 0.05; data not shown).
In the B-LONG study, known-groups validity was demonstrated for the 'Treatment' domain of the Haem-A-QoL when assessing the total number of bleeds in the 12 months prior to study entry, dichotomized at the median of 3 bleeds for this study (P < 0.05; data not shown).
Convergent validity. Convergent validity, reflected by baseline correlations of the Haem-A-QoL with measures of joint impairment (mHJHS) and health status (EQ-5D index score), was demonstrated in the A-LONG trial data. Pearson correlation analyses revealed a strong (│r│ ≥ 0.60) negative correlation between the EQ-5D index (both UK and US scorings) and Haem-A-QoL 'Total Scores,' 'Physical Health' domain scores and 'Feelings' domain scores at baseline (Table 5) .
Moderate negative relationships (0.30 < │r│ < 0.60) were observed between the EQ-5D scores and the 'View of Self,' 'Sports and Leisure,' 'Work and School,' 'Treatment,' 'Future' and 'Partnership and Sexuality' domains of the Haem-A-QoL. In Responsiveness. Responsiveness was assessed for A-LONG trial data by examining the correlation of changes (from baseline to 28 weeks) in Haem-A-QoL domain scores and 'Total Score' with changes in EQ-5D scores, the change in activity measure and bleeding rates. Change score correlations with the EQ-5D (UK) and EQ-5D (US) were moderate for the Haem-A-QoL 'Total Score' (r = À0.33 and r = À0.34 respectively) and the 'Physical Health' (r = À0.35 and r = À0.40 respectively) and 'Feelings' (r = À0.54 and r = À0.57 respectively) domains, demonstrating the sensitivity to change for these outcome measures in the A-LONG data (P < 0.03).
The ability of the Haem-A-QoL to detect change over time (baseline to Week 26), as measured by correlation of Haem-A-QoL change scores with change in other clinical measures in the B-LONG trial, yielded few notable relationships. A moderate correlation was observed between the 'Sports and Leisure' (r = 0.38) domain and the change in activity measure; the 'Sports and Leisure' domain was also moderately correlated with change in ABR and traumatic bleed rate (r = 0.34 and r = 0.33 respectively).
Although differences were not statistically significant, mean change score comparisons (Fig. 2) between the A-LONG treatment arms demonstrated a trend that mean improvements in the Haem-A-QoL 'Total Score' (À3.2 and À3.4) were similar for the individualized prophylaxis and weekly prophylaxis arms, respectively, compared with limited change in the episodic treatment group (À1.1). This pattern was also observed for the B-LONG treatment arms at 26 weeks (Fig. 2) , where the individualized interval prophylaxis arm had an improved mean change 'Total Score' (À4.0) similar to the weekly prophylaxis arm (À6.5).
Discussion
Patients with haemophilia experience improvements in HRQoL with prophylactic treatment compared with episodic treatment [19, 20] . The short-and long-term benefits to HRQoL of new longer acting clotting factor concentrates was assessed using the Haem-A-QoL in adults with severe haemophilia A or B in two recent Phase 3 clinical trials, A-LONG and B-LONG respectively. These data provided the opportunity to assess the reliability, validity and sensitivity to change over time of the Haem-A-QoL in an international, adult male population with haemophilia. In both studies, the greatest mean and median HRQoL impairments at baseline were observed in the previously identified key Haem-A-QoL domains of 'Sports and Leisure' and 'Physical Health' [21] . Internal consistency reliability, as assessed by Cronbach's alpha was adequate (a > 0.70) for nine of 10 Haem-A-QoL domains and for the 'Total Score' in both trials. In A-LONG, comparisons of mean Haem-A-QoL domain scores and 'Total Scores' by participant response levels in EQ-5D domains [Level 1 (no problems) vs. Levels 2 or 3 (problems)] demonstrated the known-groups validity of eight of 10 Haem-A-QoL domains and the 'Total Scores'. Comparisons between subjects in A-LONG with and without bleeds in the past 12 months also showed important differences in most Haem-A-QoL baseline domains and the 'Total Score'. In B-LONG, comparisons between subjects with <3 bleeds or ≥3 bleeds in the past 12 months demonstrated the known-groups validity of the 'Treatment' domain of the Haem-A-QoL.
Convergent validity was tested by correlating baseline scores of the Haem-A-QoL with the EQ-5D utility index and the mHJHS, which measures joint impairment. These analyses revealed a strong negative correlation between 'Total Scores' on the EQ-5D index and the Haem-A-QoL, and between the EQ-5D index and the 'Physical Health' and 'Feelings' domains of the Haem-A-QoL. Moderate negative relationships were observed between EQ-5D scores and six Haem-A-QoL domain scores. The moderate correlations of five domain scores and 'Total Score' on the Haem-A-QoL with mHJHS scores at baseline in the A-LONG trial further support the instrument's construct validity.
These baseline results compare favourably with those of the original Haem-A-QoL validation that was Table 4 . Known-group validity: comparison of Haem-A-QoL mean (SD) baseline score by response levels in EQ-5D domains in the A-LONG study. conducted in the Italian COCHE study, an observational study of 233 adult subjects with haemophilia A and B [8, 9] . In the COCHE study, the only other published validation study of the Haem-A-QoL, internal consistency reliability estimates using Cronbach's alpha ranged from 0.74 to 0.88 for the Haem-A-QoL domains, and a = 0.96 for the 'Total Score'. Convergent validity was strong for the Haem-A-QoL 'Physical Health' domain and 'Total Score' when correlated at baseline with the SF-36 physical component summary score; the 'Feelings' and 'View of Self' domains correlated significantly with the mental component summary score of the SF-36. Known-groups validity was investigated using comparisons of haemophilia severity groups in the original 2005 validation study; however, all subjects in the A-LONG and B-LONG studies had severe haemophilia. The Haem-A-QoL's responsiveness, or the sensitivity to change over time, was not reported in the COCHE study [8, 9] . The 6-month A-LONG change score correlations with the EQ-5D were moderate for the Haem-AQoL 'Total Score,' 'Physical Health' and 'Feelings' domains, demonstrating the sensitivity to change for these outcome measures in the A-LONG data. Although differences were not statistically significant, mean change score comparisons between the A-LONG treatment arms supported a trend that improved mean change in the Haem-A-QoL 'Total Scores' would be similar for the individualized and weekly prophylaxis arms, compared with limited change in the episodic treatment group. This pattern was also observed for the B-LONG treatment arms at 26 weeks, where the improvements in mean scores from baseline were similar in the individualized interval prophylaxis and fixed weekly prophylaxis arms.
It is also important to note that some Haem-A-QoL domains did demonstrate strong and consistent validity in these analyses; nonetheless, the 'Total Score', which combines all domain scores, did have strong psychometric support. Future research is needed to determine if fewer domains and items can accurately assess relevant aspects of quality of life, especially when used in haemophilia clinical trials.
Current therapies for haemophilia focus on infusions of factor concentrates; prophylactic administration of these agents can prevent and improve chronic joint disease and improve patients' overall quality of life and functional independence [1] . However, the time demands and compliance requirements associated with this treatment regimen are commonly cited barriers to utilization of and adherence to prophylaxis vs. episodic treatment [22, 23] . Therefore, prophylactic therapies that require less frequent administrations (e.g. once to twice weekly) could improve patient compliance, leading to improved clinical outcomes [24] and better quality of life [20, 25] ; more comparative studies will be needed to confirm this association.
This investigation of the measurement properties of the Haem-A-QoL has several limitations. First, because haemophilia is rare, the number of subjects with Haem-A-QoL data in A-LONG and B-LONG was small, despite enrolment across six continents, thus limiting more advanced analyses, such as exploratory factor analysis or Rasch/item response theory modelling. Nevertheless, these were among the largest registrational clinical trials conducted to date in people with haemophilia. The exclusion of other instruments that measured concepts directly related to HRQoL is also a limitation, especially in the B-LONG study. In addition, the B-LONG study did not measure HRQoL in the episodic treatment arm, which limited the ability to assess the psychometric properties of the Haem-A-QoL in this treatment group in subjects with haemophilia B. Due to sample size considerations, our responsiveness analyses were limited to only 6 months of treatment. Moreover, the number of respondents completing all of the items in each of the Haem-A-QoL domains varied, which may have introduced bias when comparing and evaluating across these domains and the 'Total Score'. Despite the potential for confounders, the general consistency observed in these analyses is unlikely to have been affected by these limitations. These psychometric analyses of the Haem-A-QoL using A-LONG and B-LONG clinical trial data reinforce the reliability, validity and ability of this instrument to detect change over time and support its usefulness to measure HRQoL in an adult multinational population with severe haemophilia A or B.
